Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, multicenter study to evaluate the efficacy and safety of the combination of valsartan/HCTZ [hydrochlorothiazide]/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.

Next Previous
X
Search
Trial Profile

An 8-week, multicenter study to evaluate the efficacy and safety of the combination of valsartan/HCTZ [hydrochlorothiazide]/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/valsartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide; Valsartan
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 07 Nov 2011 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
    • 18 Dec 2009 Secondary efficacy and tolerability analysis published in Advances in Therapy.
    • 09 May 2009 Results presented at the 24th Annual Scientific Meeting of the American Society of Hypertension

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top